A single dose of gyroctocogen fitelparvovec significantly reduced the mean annual total bleeding rate in patients with moderate to severe hemophilia A.
Diloctocogene fitelparvovec has been demonstrated to be superior to factor VIII prophylaxis in reducing annualized bleeding rates in patients with moderate to severe hemophilia A.
Leave a comment
